Understanding SNPs and Complex Disease Genetics through GWAS

General Localization Trends: Observations from Genome-Wide Association Studies (GWAS) indicate that the majority of identified Single Nucleotide Polymorphisms (SNPs) do not actually reside within genes, and a significant portion are not even located in proximity to genes.
Breakdown of SNP Locations (Based on Complex Disease Associations):
- Coding Exons: Approximately $20\%$ of identified SNPs lie within coding exons.
- Non-Coding and Intronic Regions (Near Genes): Approximately $40\%$ of these SNPs (roughly half of the remaining $80\%$ ) are found in non-coding or intronic regions situated near genes.
- Distal Non-Coding Regions: The remaining $40\%$ of SNPs associated with complex diseases are located in areas of the genome that are not near any genes.
Interpretative Challenges: The distribution of these polymorphisms poses a significant challenge for researchers attempting to interpret the biological mechanism of how these distant polymorphisms exert their effects.

Individual Effect Magnitude: The observed effect size of individual SNPs on complex conditions is generally very low or small. This aligns with the theoretical prediction that such diseases are not caused by single major mutations.
The Susceptibility Model: Complex diseases are believed to result from a combination of numerous small genetic effects acting in aggregate. This cumulative genetic load creates a state of susceptibility, which then requires interaction with environmental factors for the disease to manifest.
Example: Type 2 Diabetes (T2D):
- Historical Context: Identification of variants primarily occurred in the mid-to-late $2000s$ .
- Polymorphism Count: Approximately $20$ common polymorphisms have been identified as being linked to a susceptibility for Type 2 Diabetes.
- Effect Size Measurement: In statistical terms, an effect size of $1$ indicates no effect. Most T2D-associated SNPs show effect sizes only marginally higher than $1$ , meaning they are very mild individually.
- Combined Impact: While individual effects are small, the risk becomes significantly large if an individual possesses all or most of these susceptibility variants simultaneously.

Genetic Determination: Height is estimated to be approximately $95\%$ genetically determined.
Environmental Influence: While genetics are primary, environment plays a role, specifically regarding severe nutrient restriction during development (in utero or during early growth stages). However, if basic nutritional requirements are met, height is largely determined by the height of the parents.
Complexity vs. Mendelian Inheritance: Despite its high heritability, height is a complex (polygenic) trait rather than a Mendelian one, as it is controlled by many genes rather than a single locus. It serves as a primary model for understanding the genetics of complex traits.
The 2010 Nature Study Analysis:
- Scope of Data: Researchers aggregated data from $46$ separate global studies.
- Sample Size: The study involved nearly $200,000$ individuals.
- Genetic Findings: The investigation identified hundreds of variants across more than $180$ different genetic locations in the human genome.
- Pathways: These variants tended to cluster near genes involved in at least $6$ distinct biological pathways.
- The "Missing Heritability" Problem: Despite the massive size of the study, the identified variants only explained approximately $10\%$ of the genetic basis of height. This highlights that many aspects of the genetics of complex conditions remain poorly understood and difficult to pinpoint.

Institutional Collaboration: Large-scale GWAS require massive international cooperation. A typical major paper in this field includes a list of authors so extensive that it must appear at the end of the document, reflecting the involvement of numerous institutions and hundreds of researchers.
Current Limitations: Despite the sheer size and resource intensity of these studies, they have not yet provided a full understanding of the genetic basis of complex conditions.

Value of Identifying Variants: Even when effect sizes are small, the primary value of identifying these variants lies in uncovering new genes or biological pathways, providing novel insights into disease pathology.
Age-Related Macular Degeneration (AMD):
- Original View: Historically considered purely a degenerative disorder.
- GWAS Finding: Studies identified genes involved in the complement immune pathways.
- Clinical Impact: This shifted understanding to include the immune system's role, opening new therapeutic avenues.
Crohn's Disease:
- GWAS Finding: Identified genes involved in autophagy and the immune response to microbes.
Asthma:
- Original View: Generally considered a disease of immune system overreaction.
- GWAS Finding: Identified novel genes important in the lung epithelium (the lining or "skin" of the lung).
- Significance: This discovery directed research toward the physical structure of the lung rather than focusing exclusively on the immune response.
Obesity and the FTO Gene:
- The FTO Gene: Mentioned as a notable success story for GWAS in identifying novel pathways.
- Conclusion: When GWAS results are followed by biological studies to understand the variants, they can highlight potential therapeutic approaches and uncover previously unknown disease mechanisms.